Acurx Pharmaceuticals Valuation
Is ACXP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Share Price vs Fair Value
What is the Fair Price of ACXP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ACXP?
Other financial metrics that can be useful for relative valuation.
| What is ACXP's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$32.14m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does ACXP's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.2x | ||
BIVI BioVie | 3.6x | n/a | US$27.0m |
AIM AIM ImmunoTech | 2.2x | 9.4% | US$21.2m |
FRLN Freeline Therapeutics Holdings | 0.9x | 60.7% | US$28.3m |
BIAF bioAffinity Technologies | 5.8x | n/a | US$29.8m |
ACXP Acurx Pharmaceuticals | 6.9x | 7.4% | US$32.1m |
Price to Earnings Ratio vs Industry
How does ACXP's PE Ratio compare vs other companies in the US Biotechs Industry?
Price to Book Ratio vs Fair Ratio
What is ACXP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 6.9x |
| Fair PB Ratio | n/a |
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?